Background/ Purpose Belimumab was approved for the treatment of non-renal SLE in 2011 and has been previously associated with a lower risk of damage progression when compared with prior ‘usual care.’ ...

In the absence of cures for multi-system inflammatory disease, therapies aim to dampen long-term inflammation, control symptoms and prevent tissue damage. Glucocorticoids (GC) are a key ...

Background Single-cell RNA-sequencing (scRNA-seq) has been recently applied in systemic lupus erythematosus (SLE) to define distinct cellular composition and transcriptional signatures, greatly ...

O37 Male gender, educational level, disease activity, prednisone daily dose and previous medical adherence are predictive of medical adherence in systemic lupus erythematosus patients – Data from the ...

Original research: Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort (1 July, 2025 ...

Conclusion The SLE-DAS cut-off for SDA provides an accurate definition of SDA in SLE, with good discriminative power and consistent associations with worse HR-QoL. This SLE-DAS definition enhances ...

Introduction It remains unclear how the presence of renal involvement will affect the cardiovascular (CV) risk factors and complications in patients with SLE.Methods We conducted a systematic review ...

Objective Patients with SLE have a well-known increased risk of major comorbidities, although they are also very heterogeneous in terms of the prevalence of comorbid conditions. The relationships of ...

Objective Discrepancies in illness representations between patients and physicians result in treatment difficulties, decreased well-being of patients and misunderstandings and disrupted communication.

Objectives To evaluate the Systemic Lupus International Collaborating Clinics-Frailty Index (SLICC-FI) as a predictor of hospitalisations in patients with SLE from a Latin American cohort.Methods ...

Objective To explore the efficacy of initial treatment of newly diagnosed childhood-onset lupus nephritis (cLN) with combination of belimumab and either cyclophosphamide, mycophenolate mofetil, ...

Background Systemic lupus erythematosus (SLE) is a complex disease caused by interplay of genetic predisposition and environmental triggers. Strong genetic component in lupus supported by familial ...